{
  "abstract": "Background In this phase 1/2 study, we assessed the safety/antitumor activity of farletuzumab ecteribulin (FZEC), a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in patients with pretreated solid tumors. Methods Patients aged ≥18 years with measurable disease (per RECIST v1.1) were included. Patients with ovarian cancer (OC), endometrial cancer (EC), TNBC, and NSCLC were included in Dose-Escalation (0.9 mg/kg and 1.2 mg/kg IV Q3W). Patients with OC/EC were included for Dose-Confirmation (25 mg/m 2 and 33 mg/m 2 IV Q3W) and Dose-Optimization-part-A (8 mg/m 2 D1/D8/D15, 12 mg/m 2 D1/D8; 25 mg/m 2 D1 + steroid IV Q3W). Results Eighty-nine patients were enrolled (median age: 67.0 years); most (88.7%) patients with OC and 50.0% patients with EC received ≥2 previous anticancer regimens. In Dose-Escalation ( n = 25), interstitial lung disease (ILD)/pneumonitis occurred in 40% of patients. The dosing methodology was amended to body surface area-based dosing in subsequent study parts as an ILD/pneumonitis-mitigation strategy. In Dose-Confirmation ( n = 24), 33.3% of patients experienced ILD/pneumonitis. In the 25 mg/m 2 cohort, all ILD/pneumonitis events were grade-1/2. Evaluation of the 33 mg/m 2 dose was discontinued due to observed ILD/pneumonitis. Dose equivalents of 25 mg/m 2 were further evaluated in Dose-Optimization-part-A, with steroids/fractionated dosing (to mitigate ILD/pneumonitis). Patients receiving 8 mg/m 2 D1/D8/D15 experienced no ILD/pneumonitis and achieved more responses versus other regimens, but the subgroup sizes were small. With steroids, incidence of ILD/pneumonitis was similar, but onset appeared delayed. Conclusions Fractionated doses of FZEC reduced the risk of ILD/pneumonitis and showed preliminary antitumor activity. Dose-Optimization-part-B will test additional FZEC fractionated doses (alone and in combination with lenvatinib) and concomitant steroid use. Clinical Trial Registration #: NCT04300556.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 26,
  "authors": [
    {
      "name": "Robert Wenham"
    },
    {
      "name": "Isabelle Ray-Coquard"
    },
    {
      "name": "Rebecca Kristeleit"
    },
    {
      "name": "Daniela Matei"
    },
    {
      "name": "Sharad Ghamande"
    },
    {
      "name": "Ana Oaknin"
    },
    {
      "name": "Jonathan Berek"
    },
    {
      "name": "J Alejandro Perez-Fidalgo"
    },
    {
      "name": "Pau Guillén Sentís"
    },
    {
      "name": "Eva Guerra Alia"
    },
    {
      "name": "June Hou"
    },
    {
      "name": "Phillipe Follana"
    },
    {
      "name": "Lauriane Eberst"
    },
    {
      "name": "Andrew Clamp"
    },
    {
      "name": "Jean-Sebastien Frenel"
    },
    {
      "name": "Patricia Roxburgh"
    },
    {
      "name": "Robert Jones"
    },
    {
      "name": "Patricia Pautier"
    },
    {
      "name": "Amanda Jackson"
    },
    {
      "name": "Deborah Armstrong"
    },
    {
      "name": "Tingting Song"
    },
    {
      "name": "Maiko Nomoto"
    },
    {
      "name": "Natalyn Hawk"
    },
    {
      "name": "Rachael Scott"
    },
    {
      "name": "Vicky Makker"
    },
    {
      "name": "J. Alejandro Perez-Fidalgo"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/074jnpmt6ywxx.bib",
  "cited_by": 0,
  "doi": "10.1016/j.ygyno.2026.08.023",
  "fulltext_url": null,
  "id": "074jnpmt6ywxx",
  "issns": [
    "0090-8258",
    "1095-6859"
  ],
  "landing_url": "https://hal.science/hal-05801041v1",
  "language": "en",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "hal",
      "0.sdv"
    ],
    [
      "hal",
      "1.sdv.spee"
    ],
    [
      "openalex",
      "2743|Ovarian cancer diagnosis and treatment"
    ]
  ],
  "openalex": "W7220425063",
  "pdf_url": "https://www.gynecologiconcology-online.net/article/S0090-8258(26)02115-3/pdf",
  "pmcid": null,
  "pmid": "42833056",
  "published": "2026-10-15",
  "publisher": "Elsevier",
  "ris": "https://research.draconitic.com/paper/074jnpmt6ywxx.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:57Z",
      "native_id": "hal-05801041",
      "source": "hal",
      "url": "https://hal.science/hal-05801041v1"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "hal:0.sdv",
      "subfield": "general"
    },
    {
      "field": "medicine",
      "origin": "hal:1.sdv.spee",
      "subfield": "epidemiology-public-health"
    }
  ],
  "title": "Farletuzumab ecteribulin, a folate receptor alpha (FRα) antibody-drug conjugate, in select advanced cancers: An open-label, multicenter, phase 1/2 dose-finding study",
  "title_text": "Farletuzumab ecteribulin, a folate receptor alpha (FRα) antibody-drug conjugate, in select advanced cancers: An open-label, multicenter, phase 1/2 dose-finding study",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:57Z",
  "url": "https://research.draconitic.com/paper/074jnpmt6ywxx",
  "venue": "Gynecologic Oncology",
  "versions": []
}